

Antibody-mediated Rejection Market Size, Trends, and Forecast

The Antibody-mediated Rejection Market is at the forefront of post-transplant immunology, reflecting evolving market trends and significant industry size growth. Our analysis underscores the rising necessity for targeted therapies to mitigate alloimmune responses, driving business growth across pharmaceuticals and biotech and shifting industry share in favor of specialized biologics. With increasing adoption of advanced immunomodulators, patient outcomes and operational efficiencies have improved markedly in 2024–2025.

Market Size and Overview

The antibody-mediated rejection market is estimated to be valued at USD 142.7 Mn in 2025 and is expected to reach USD 331.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 12.8% from 2025 to 2032.

Our [Antibody-mediated Rejection Market](#) forecast highlights accelerated market revenue gains driven by novel monoclonal antibody approvals and expanded clinical protocols in 2024–2025. The evolving market report also underscores emerging market opportunities and shifting market trends as tailored immunotherapies become central to post-transplant management.

Market Segments

In segmentation analysis, the Antibody-mediated Rejection Market report defines three core market segments: Treatment Type, End User, and Therapeutic Approach. Treatment Type includes Plasmapheresis, Intravenous Immunoglobulin (IVIG), Monoclonal Antibodies, and Complement Inhibitors; Monoclonal Antibodies dominated revenue at USD 58.3 Mn in 2024 and captured the largest market share, whereas Complement Inhibitors recorded the fastest expansion with a 15% year-on-year increase in 2025.

End User comprises Hospitals, Specialty Clinics, and Research Institutes; Hospitals continue to lead in industry size, while Specialty Clinics are projected to grow at a 14% CAGR by 2025 driven by outpatient infusion services. Therapeutic Approach covers Induction, Maintenance, and Rescue therapies—Maintenance therapies command the highest uptake, but Rescue protocols surged fastest following guideline updates in early 2025.

Market Drivers

One pivotal market driver fueling market growth is the surge in global organ transplant volumes and favorable regulatory frameworks for immunotherapy. In 2024, the International Transplant Registry reported a 9% rise in allograft procedures worldwide, amplifying demand for targeted AMR interventions. Additionally, accelerated approval pathways by regulatory bodies in key regions spurred product launches—IVIG formulations saw a 12% sales uptick in 2025 compared to 2023. These policy-level developments have mitigated prior market restraints related to clinical trial durations, thereby strengthening market dynamics and expanding market opportunities across emerging markets. This influx of procedures has widened the market scope and intensified competition for market share.

Segment Analysis

In our segment analysis of Treatment Type, Monoclonal Antibodies emerged as the dominant sub-segment, generating USD 58.3 Mn in Antibody-mediated Rejection Market revenue in 2024, driven by widespread clinical adoption of novel anti-CD20 therapies. Complement Inhibitors represent the fastest-growing niche, with revenues climbing at a 15% CAGR in 2025, as evidenced by CSL Behring's eculizumab extensions into refractory AMR cases. This market analysis highlights how tailored biologics are reshaping treatment paradigms and informs refined market growth strategies for pipeline prioritization through data-backed case studies. This sub-category's performance is significantly contributing to the overall market size and shapes strategic priorities for 2025.

